Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
SyntheX logo — Targeting the undruggable with synthetic biology-based drug...

SyntheX

Targeting the undruggable with synthetic biology-based drug discovery platforms

Founded 2016 United States San Francisco, United States 26 employees Venture round Total: $11.58M Biotechnology, Health and Wellness +2

General Information

Company Name SyntheX
Founded Year 2016
Location United States San Francisco, United States
Employees 26
Industries Biotechnology, Health and Wellness, Life Sciences +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with SyntheX. To contact SyntheX, visit synthexlabs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SyntheX compare?

A PDF of SyntheX and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SyntheX soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SyntheX

SyntheX is a biotechnology and pharmaceutical startup founded in 2016 in the United States. The company's slogan "Targeting the undruggable with synthetic biology-based drug discovery platforms" encapsulates its focus on utilizing synthetic biology to revolutionize drug discovery. SyntheX's approach involves using genetically engineered circuits for intracellular drug selection, instead of traditional in-vitro screening, enabling the discovery of unbiased compounds with novel modes of action. Their proprietary technologies, including ToRPPIDO and ToRNeDO, are designed to identify disruptors of protein-protein interactions (PPIs) and functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase. Additionally, the incorporation of DNA-encoded libraries of peptides and macrocycles allows for efficient and high-throughput production and selection of molecules. The last investment in SyntheX was a significant $5.18M Venture Round investment on December 29, 2023. The specifics of the investors in this round are not currently disclosed. SyntheX's primary focus is on oncology, positioning the company to make impactful contributions to cancer treatment and potentially disrupt the existing landscape of drug discovery in the field.

Business keywords: Synthetic Biology, Drug Discovery, Oncology, Genetic Engineering, Protein-Protein Interactions, Targeted Protein Degradation, Cancer Genetics, Therapeutics, Synthetic Lethality, Biologics, Ras, Molecular Glues, Peptides, Functional Selection

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $5.18M -
29 Dec 2023
Corporate Round Undisclosed 1
Bristol-Myers Squibb
04 Oct 2022
Convertible Note Undisclosed 2
SOSV indiebio
SOSV, indiebio
27 Jul 2022
Convertible Note Undisclosed 2
SOSV indiebio
SOSV, indiebio
03 Sep 2020
Seed Round $6.15M 4
SOSV 8VC Oriza Ventures
SOSV, 8VC +2
01 Mar 2017
Convertible Note $250.00K 2
SOSV indiebio
SOSV, indiebio
10 Mar 2016

SyntheX Alternatives & Competitors

View All Alternatives
SyntheX vs
Magnet Biomedicine
Magnet Biomedicine United States

Revolutionizing Human Medicine with Molecular Glues

Series A
42 employees
Biotechnology, Pharmaceutical
Compare SyntheX vs Magnet Biomedicine
SyntheX vs
IDEAYA Biosciences
IDEAYA Biosciences United States

Synthetic lethality precision medicine oncology company pursuing– an emerging class of precision med...

Post-IPO Equity
264 employees
Biotechnology, Health Care
Compare SyntheX vs IDEAYA Biosciences
SyntheX vs
A-Alpha Bio
A-Alpha Bio United States

The protein-protein interaction company

Grant
50 employees
Biotechnology, Health Care
Compare SyntheX vs A-Alpha Bio
Also compare with: SyntheX vs Tentarix Biotherapeutics Tentarix Biotherapeutics SyntheX vs C4 Therapeutics, Inc. C4 Therapeutics, Inc. View all alternatives

FAQ About SyntheX

Targeting the undruggable with synthetic biology-based drug discovery platforms
SyntheX was founded in 2016.
SyntheX is headquartered in San Francisco, United States.
SyntheX operates in Biotechnology, Health and Wellness, Life Sciences and Pharmaceutical. Its work centres on Synthetic Biology, Drug Discovery, Oncology and Genetic Engineering.
SyntheX has approximately 26 employees.
SyntheX has completed 6 funding rounds, raising a total of $11.58M. The latest funding stage is Venture round.
Top alternatives and competitors to SyntheX include Magnet Biomedicine, IDEAYA Biosciences, A-Alpha Bio, Tavros Therapeutics, Repare Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SyntheX and Magnet Biomedicine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SyntheX, https://bouncewatch.com/company/synthex, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes